Hepatic Encephalopathy - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 72
Inquire Before Buying
This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Hepatic Encephalopathy - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 5, 2, 2 and 1 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Hepatic Encephalopathy - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
AlfaSigma SpA
Cosmo Pharmaceuticals NV
Ferring International Center SA
Gilead Sciences Inc
MallInckrodt Plc
Spherium Biomed SL
Synlogic Inc
Umecrine Cognition AB
Hepatic Encephalopathy - Drug Profiles
GR-3027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin SSD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYNB-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THDP-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting
Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting 2017
Jun 01, 2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
May 26, 2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease
Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
Nov 10, 2016: Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
Nov 02, 2016: Ocera Therapeutics: Update on OCR-002
Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatic Encephalopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hepatic Encephalopathy - Pipeline by AlfaSigma SpA, H2 2018
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, H2 2018
Hepatic Encephalopathy - Pipeline by Ferring International Center SA, H2 2018
Hepatic Encephalopathy - Pipeline by Gilead Sciences Inc, H2 2018
Hepatic Encephalopathy - Pipeline by MallInckrodt Plc, H2 2018
Hepatic Encephalopathy - Pipeline by Spherium Biomed SL, H2 2018
Hepatic Encephalopathy - Pipeline by Synlogic Inc, H2 2018
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2018
Hepatic Encephalopathy - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Hepatic Encephalopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 2000 Onwards        Pages: 601
    Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape. Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarrin......
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 2000 Onwards        Pages: 243
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape. Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty li......
  • Global Esomeprazole Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 93
    This report studies the global Esomeprazole market status and forecast, categorizes the global Esomeprazole market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Esomeprazole market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major man......
  • 2018-2023 Global Gastrointestinal Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 164
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Gastrointestinal market for 2018-2023. Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gast......
  • 2018 Top 5 Gastrointestinal Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 145
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gastrointestinal is in a slight decreasing trend, and the gross margin is 63% in 2015. Europe region is the largest supplier of Gastrointestinal, with a production revenue marke......
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 35
    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape. Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called func......
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 91
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape. Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. T......
  • Colitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 108
    Colitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory ......
  • Primary Sclerosing Cholangitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 111
    Primary Sclerosing Cholangitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs